NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis $1.01 -0.03 (-2.88%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$1.01▼$1.0750-Day Range$0.99▼$5.0752-Week Range$0.92▼$17.17Volume19,905 shsAverage Volume69,864 shsMarket Capitalization$39.51 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get AEON Biopharma alerts: Email Address AEON Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside494.1% Upside$6.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.91) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.71 out of 5 starsMedical Sector842nd out of 914 stocksPharmaceutical Preparations Industry398th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AEON. Previous Next 0.0 Dividend Strength Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEON. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.00% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($0.91) to ($0.87) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research25th AmendmentIt's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.But what happens next? About AEON Biopharma Stock (NASDAQ:AEON)AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.Read More AEON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEON Stock News HeadlinesMay 29, 2024 | markets.businessinsider.comAEON Biopharma Cuts 55% Of Workforce, Terminates CFO To Preserve Cash; Stock Up In Pre-marketMay 29, 2024 | globenewswire.comAEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction PlanJuly 2, 2024 | StockEarnings (Ad)Re: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4. May 15, 2024 | finance.yahoo.comAEON Biopharma, Inc. (AEON)May 14, 2024 | globenewswire.comAEON Biopharma Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comAEON Biopharma Provides Update on Development PipelineMay 7, 2024 | markets.businessinsider.comMaintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 SetbackMay 3, 2024 | msn.comNewly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here WhyJuly 2, 2024 | StockEarnings (Ad)Re: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4. May 3, 2024 | finance.yahoo.comUS Equity Markets Close Higher Friday Following Weak Jobs ReportMay 3, 2024 | markets.businessinsider.comAEON Says Preliminary Results From Phase 2 Interim Analysis Of ABP-450 Fails To Meet Primary GoalMay 3, 2024 | globenewswire.comAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic MigraineApril 18, 2024 | markets.businessinsider.comAEON Biopharma: Buoyant Prospects Following FDA Alignment on Migraine StudiesMarch 30, 2024 | globenewswire.comCORRECTION -- AEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | seekingalpha.comLenz stock rallies 22% amid bullish note by Piper SandlerMarch 21, 2024 | investing.comAEON Biopharma secures $15 million in private placementMarch 19, 2024 | globenewswire.comAEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of MigraineMarch 19, 2024 | globenewswire.comAEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase AgreementsFebruary 26, 2024 | edition.cnn.comAEON Biopharma, Inc. Class AFebruary 6, 2024 | finanznachrichten.deDaewoong Pharmaceutical Co., Ltd.: Daewoong Pharmaceutical Announces 2023 Financial ResultsFebruary 1, 2024 | morningstar.comAeon Kyushu Co Ltd 2653January 31, 2024 | seekingalpha.comAEON.WS AEON Biopharma, Inc. WT EXP 072128January 18, 2024 | finance.yahoo.comAEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin ConferenceJanuary 10, 2024 | investing.comAeon Fantasy Co Ltd (4343)December 20, 2023 | morningstar.comXeris Biopharma Holdings Inc XERSSee More Headlines Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CUSIPN/A CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+494.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,630,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-145.99% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.25Miscellaneous Outstanding Shares39,120,000Free Float31,298,000Market Cap$39.51 million OptionableNot Optionable Beta0.41 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Marc Forth (Age 52)President, CEO & Director Comp: $1.13MDr. Chad K. Oh M.D. (Age 65)Chief Medical Officer Comp: $587.4kMr. Peter A. Reynolds CPA (Age 66)Chief Financial Officer Mr. Alex Wilson (Age 37)Executive VP, Chief Legal Officer & Corporate Secretary Key CompetitorsFibroBiologicsNASDAQ:FBLGBiomea FusionNASDAQ:BMEAOrganigramNASDAQ:OGIPuma BiotechnologyNASDAQ:PBYIInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsShaolin Capital Management LLCSold 895,740 shares on 5/17/2024Ownership: 0.057%Vanguard Group Inc.Bought 549,207 shares on 5/10/2024Ownership: 2.008%Crown Holdings Grou StrathspeySold 7,380,394 sharesTotal: $73.80 M ($10.00/share)View All Insider TransactionsView All Institutional Transactions AEON Stock Analysis - Frequently Asked Questions Should I buy or sell AEON Biopharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AEON Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEON shares. View AEON analyst ratings or view top-rated stocks. What is AEON Biopharma's stock price target for 2024? 1 analysts have issued 1 year price objectives for AEON Biopharma's stock. Their AEON share price targets range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next year. This suggests a possible upside of 494.1% from the stock's current price. View analysts price targets for AEON or view top-rated stocks among Wall Street analysts. How have AEON shares performed in 2024? AEON Biopharma's stock was trading at $7.20 on January 1st, 2024. Since then, AEON shares have decreased by 86.0% and is now trading at $1.01. View the best growth stocks for 2024 here. How were AEON Biopharma's earnings last quarter? AEON Biopharma, Inc. (NASDAQ:AEON) released its earnings results on Tuesday, May, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.03. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEON) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored25th AmendmentIt's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.